Literature DB >> 12607215

In-vitro immunomodulatory effects of haloperidol and perazine in schizophrenia.

J Kowalski1, P Blada, K Kucia, T Lawniczek, A Madej, D Belowski, Z S Herman.   

Abstract

There are some reports describing concurrent changes in lymphocytic and monocytic activities in schizophrenia. In this study we investigated T cell activity in schizophrenic patients by measuring the release of interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) by T cells and the percentages of CD4+ and CD8+ cells in blood. The release of IL-2 and sIL-2R by T cells was evaluated in dilute whole blood after in-vitro stimulation with phytohemagglutinin. IL-2 levels and the percentage of CD4-cells tended to decrease and sIL-2R levels decreased significantly in schizophrenic patients. Haloperidol and perazine significantly decreased IL-2 levels and increased sIL-2R levels and the percentage CD4-cells. IL-2 and sIL-2R levels were lower in patients with a predominance of positive symptoms. The neuroleptic-induced increase in sIL-2R levels was higher in patients with a predominance of positive symptoms compared with those in whom both positive and negative symptoms were severe. The study has shown that T-cell activity is reduced in schizophrenia and that neuroleptics may have immunomodulatory properties.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12607215     DOI: 10.3109/15622970009150591

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  2 in total

1.  Soluble cytokine receptors (sIL-2Rα, sIL-2Rβ) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain.

Authors:  Steven S Zalcman; Ankur Patel; Ruchika Mohla; Youhua Zhu; Allan Siegel
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

2.  Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures.

Authors:  Md Mamun Al-Amin; Mir Muhammad Nasir Uddin; Hasan Mahmud Reza
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-12-24       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.